Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 394-401

  Oizumi, Satoshi ^a   Deyev, Vadim ^a   Yamazaki, Koichi ^a   Schreiber, Taylor ^a   Strbo, Natasa ^a   Rosenblatt, Joseph ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

B cell de.ciency depletion; Frequent vaccination; Secreted HSP gp96 vaccine; Tumor induced immunosuppression

Indexed keywords

CHAPERONE; GLYCOPROTEIN GP 96; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LEWIS CARCINOMA; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN FC FRAGMENTS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; TUMOR ESCAPE;

EID: 42649094145     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816bc74d     Document Type: Article

References (25)

1. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636-645.
2. + regulatory T-cells in cancer. Semin Cancer Biol. 2006;16:73-79.
3. Sotomayor EM, Borrello I, Rattis FM, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001;98:1070-1077.
4. + T cells. Nat Immunol. 2005;6:593-599.
5. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20:395-425.
6. Srivastava PK, Heike M. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Semin Immunol. 1991;3:57-64.
7. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178:1391-1396.
8. Arnold D, Faath S, Rammensee H, et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med. 1995;182: 885-889.
9. Ramirez SR, Singh-Jasuja H, Warger T, et al. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones. 2005;10:221-229.
10. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000;191:1965-1974.
11. Strbo N, Oizumi S, Sotosek-Tokmadzic V, et al. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 2003;18:381-390.
12. Yamazaki K, Nguyen T, Podack ER. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol. 1999;163:5178-5182.
13. Oizumi S, Strbo N, Pahwa S, et al. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J Immunol. 2007;179:2310-2317.
14. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000;1:151-155.
15. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA. 2004;101: 6128-6133.
16. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem. 2002;277:20847-20853.
17. Ikawa M, Yamada S, Nakanishi T, et al. "Green mice" and their potential usage in biological research. FEBS Lett. 1998;430:83-87.
18. Ohe Y, Zhao D, Saijo N, et al. Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. Hum Gene Ther. 1995;6:325-333.
19. Hogquist KA, Jameson SC, Heath WR, et al. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17-27.
20. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290.
21. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299-9307.
22. Perricone MA, Smith KA, Claussen KA, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother. 2004;27:273-281.
23. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
24. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005; 117:574-586.
25. + CD25 high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur J Immunol. 2007;37:282-291.